{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:09:52Z","timestamp":1780096192908,"version":"3.54.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.amjmed.2017.09.010","type":"journal-article","created":{"date-parts":[[2017,9,22]],"date-time":"2017-09-22T02:30:24Z","timestamp":1506047424000},"page":"200.e1-200.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy"],"prefix":"10.1016","volume":"131","author":[{"given":"Martin S.","family":"Maron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winnie","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine B.","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy S.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan J.","family":"Rowin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Desnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry J.","family":"Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2017.09.010_bib0010","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0015","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001","journal-title":"The Online Metabolic and Molecular Bases of Inherited Disease"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0025","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0030","first-page":"67","article-title":"Angiokeratoma corporis diffusum\u2013Fabry's disease","volume":"34","author":"Colombi","year":"1967","journal-title":"Helv Med Acta"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0035","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0040","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry's disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0045","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0050","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0055","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0060","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0065","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","article-title":"Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women","volume":"12","author":"Havndrup","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0070","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study","volume":"97","author":"Hagege","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0080","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10545-013-9659-2","article-title":"Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS)","volume":"37","author":"Palecek","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0085","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jjcc.2016.05.014","article-title":"Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy","volume":"69","author":"Kubo","year":"2017","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0095","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0100","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0105","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0115","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0120","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00439-017-1779-6","article-title":"The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies","volume":"136","author":"Stenson","year":"2017","journal-title":"Hum Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0125","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1536\/ihj.16-361","article-title":"Identification of a novel GLA gene mutation, p.Ile239Met, in fabry disease with a predominant cardiac phenotype","volume":"58","author":"Csanyi","year":"2017","journal-title":"Int Heart J"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0130","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabrys disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0135","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0140","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jacc.2012.02.068","article-title":"Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives","volume":"60","author":"Maron","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0145","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jacc.2014.05.003","article-title":"Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine","volume":"64","author":"Maron","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0150","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cca.2009.02.008","article-title":"Effect of sample collection on alpha-galactosidase A enzyme activity measurements in dried blood spots on filter paper","volume":"403","author":"Olivova","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0160","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/339431","article-title":"Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype","volume":"70","author":"Ishii","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/hmg\/2.7.1051","article-title":"Mutation analysis in patients with the typical form of Anderson-Fabry disease","volume":"2","author":"Davies","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0170","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/BF03401993","article-title":"Twenty novel mutations in the alpha-galactosidase A gene causing Fabry disease","volume":"5","author":"Topaloglu","year":"1999","journal-title":"Mol Med"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0175","first-page":"S51","article-title":"The phenotypic characteristics of the p.N215S Fabry disease genotype in male and female patients: a multicenter Fabry registry study","volume":"120","author":"Germain","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0180","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1540-8167.2007.00942.x","article-title":"Significance of appropriate defibrillator shock 3 hours and 20 minutes following implantation in a patient with hypertrophic cardiomyopathy","volume":"19","author":"Almquist","year":"2008","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0190","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0195","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1161\/CIRCULATIONAHA.114.014283","article-title":"Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy","volume":"132","author":"Maron","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0200","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jacc.2009.05.006","article-title":"Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance","volume":"54","author":"Maron","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0205","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.ijcard.2012.10.076","article-title":"Screening for Fabry disease in patients with left ventricular hypertrophy","volume":"167","author":"Mawatari","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0210","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001639","article-title":"Fabry disease in families with hypertrophic cardiomyopathy: clinical manifestations in the classic and later-onset phenotypes","volume":"10","author":"Adalsteinsdottir","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0215","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1161\/01.CIR.92.4.785","article-title":"Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults","volume":"92","author":"Maron","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0220","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0225","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0230","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4\u00a0+\u00a0919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0235","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1161\/CIRCULATIONAHA.105.593558","article-title":"Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study","volume":"113","author":"Morita","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173358","article-title":"Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies","volume":"12","author":"El Dib","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0245","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/jhg.2016.78","article-title":"Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes","volume":"61","author":"Kim","year":"2016","journal-title":"J Hum Genet"},{"key":"10.1016\/j.amjmed.2017.09.010_bib0250","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000448968","article-title":"Long term treatment with enzyme replacement therapy in patients with fabry disease","volume":"134","author":"Oder","year":"2016","journal-title":"Nephron"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317309397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934317309397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:13:05Z","timestamp":1757581985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934317309397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0002934317309397"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.09.010","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2017.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}